In vivo biocompatibility of site-directed apoferritin-based nanocarrier for cardiotoxic antitumour drug doxorubicin

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62156489%3A43210%2F17%3A43912073" target="_blank" >RIV/62156489:43210/17:43912073 - isvavai.cz</a>
Alternative codes found
RIV/00216305:26620/17:PU125536
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
In vivo biocompatibility of site-directed apoferritin-based nanocarrier for cardiotoxic antitumour drug doxorubicin
Original language description
Doxorubicin (DOX), a potent anthracycline antibiotic [1], is used in conventional cancer therapy for the treatment of various solid and haematological malignancies, such as breast [2], lung [3], bladder [4] or Hodgkin lymphoma [5]. However, up to 26% of patients treated with DOX develop arrhythmia or cardiomyopathy [6]. Co-administration with cardioprotective drugs can lead to other unwanted side effects, such as the development of secondary malignancies in case of dexrazoxane [7]. This effectively limits DOX dose that can be administered to the patients [6].
Czech name
—
Czech description
—

Project
<a href="/en/project/GA17-12816S" target="_blank" >GA17-12816S: Construction of modified apoferritin nanocarriers bearing anticancer drugs and study of mechanisms enhancing their efficiency in anticancer therapy</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)